Progress of immunotherapy trials in the treatment of lung cancer
10.3760/cma.j.issn.1673-422X.2015.03.013
- VernacularTitle:肺癌免疫治疗临床试验进展
- Author:
Hao LIU
;
Hongjun GAO
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Lung neoplasms;
Clinical trial
- From:
Journal of International Oncology
2015;(3):210-213
- CountryChina
- Language:Chinese
-
Abstract:
Surgery in combination with chemotherapy and radiotherapy is the standard of lung cancer treatment,but postoperative recurrence is very common which usually leads to higher mortality and lower life quality. Immunotherapy on post-operative patients fully mobilizes the body's defense mechanisms,activates the immune cells,and kills residual cancer cells. Current research on lung cancer immunotherapy mainly includes four categories:adoptive immunotherapy,dendritic cell vaccine,non-specific antigen immune therapy and anti-gen-specific vaccine. These studies show lung cancer immunotherapy intervention can effectively reduce postop-erative residual cancer cells,reduce postoperative recurrence rate,prolong survival,significantly improve the prognosis,and is worth spreading in clinical practice.
